April 5-6, 2021 Webconference

The Longwood Healthcare Leaders meeting, April 5-6, 2021, is centered on MIT’s Koch Institute via webconference with leading biopharma CEOs, heads of R&D, top academic researchers, and healthcare investors, co-hosted by Nobel laureate and Biogen/Alnylam co-founder Phil Sharp

Speakers include Operation Warp Speed Chief Advisor Moncef Slaoui, FDA CDER Director Janet Woodcock, GSK R&D head Hal Barron, Regeneron CSO George Yancopoulos, Janssen Global R&D head Mathai Mammen, Sanofi R&D head John Reed, Genentech CEO Alexander Hardy, Novartis Institutes for BioMedical Research President Jay Bradner, Takeda R&D head Andy Plump, AbbVie Chief Strategy Officer Henry Gosebruch, Merck Chief Patient Officer and former CDC Director Julie Gerberding, BMS R&D head Rupert Vessey, Moderna CSO Melissa Moore, Alexion R&D head John Orloff, AbbVie R&D head Tom Hudson, Amgen R&D head David Reese, BIO Chair Jeremy Levin, among others.

These meetings are focused on accelerating the translation of discoveries into medicines to help patients; substantial donations enabled by these meetings benefit Life Science Cares, The Boston Foundation, BSO, Harvard Medical School, MIT, and other charities.

MONDAY, APRIL 5, 2021 | AGENDA

-- all times Eastern Standard –

 

7:00 – 7:30 | LONGWOOD FUND INTRODUCTION
Christoph Westphal, General Partner, Longwood Fund; David Steinberg, General Partner, Longwood Fund; John Lawrence, CFO, Longwood Fund; Rich Aldrich, General Partner, Longwood Fund

7:30 – 8:00 | STRATEGY IMPLEMENTATION: FROM NEWCO TO ESTABLISHED
Jeff Goldberg, CEO, Immunitas; Robert Sims, Entrepreneur-in-Residence, Third Rock; David Southwell, CEO, TScan Therapeutics; Lara Sullivan, CEO, Pyxis Oncology; K. Dane Wittrup, Professor, Chemical & Biological Engineering, Koch Institute
Moderator: Connie Chiang, Managing Director, Barclays Bank

8:00 – 8:20 | MANAGING HEALTH SYSTEMS IN A NEW ERA
Tom Sequist, Chief Patient Experience and Equity Officer, Mass General Brigham; Kevin Tabb, CEO, Beth Israel Lahey

8:20 – 8:40 | MODERATED KEYNOTE: MASSACHUSETTS GOVERNOR CHARLIE BAKER
Governor Charlie Baker
Moderator: Christoph Westphal, General Partner, Longwood Fund

8:40 – 9:00 | MODERATED KEYNOTE: OPERATION WARP SPEED
Moncef Slaoui, Chief Advisor, Operation Warp Speed
Moderator: Christoph Westphal, General Partner, Longwood Fund

9:00 – 9:30 | A NEW ERA OF COLLABORATION AND ENHANCED TRANSPARENCY
Percival Barretto-Ko, President, Astellas US; Joanne Waldstreicher, CMO, Johnson & Johnson; Julie Gerberding, Chief Patient Officer, Merck & Co., former Director, CDC;
Moderator: John Westwood, Managing Partner, Huron Consulting Group

9:30 – 10:00 | INNOVATION IN THE ROLE OF MANUFACTURING
Thierry Bernard, CEO, Qiagen; Jason Kelly, CEO, Ginkgo Bioworks; Rahul Singhvi, CEO, Resilience

10:00 – 10:30 | EXPEDITING RESEARCH FOR TREATMENTS AND CURES
Charles Albright, CSO, Affinia Therapeutics; Brad Margus, CEO, Cerevance; Rich Moscicki, EVP, Science & Regulatory Advocacy, CMO, PhRMA; Rogerio Vivaldi, President, CEO, Sigilon
Moderator: George Daley, Dean, Harvard Medical School

10:30 – 10:50 | FIRESIDE CHAT
Alexander Hardy, CEO, Genentech; Emmanuel Ligner, President, Cytiva

10:50 – 11:10 | IDENTIFYING NOVEL TECHNOLOGY
Rafael Amado, EVP, Head of R&D & CMO, Allogene; Maria Fardis, CEO, Iovance; Brett Monia, CEO, Ionis Pharmaceuticals; Alan Sachs, CSO, Thermo Fisher Scientific; Tarek Samad, CSO, Immunitas
Moderator: Michal Preminger, Head, E. North America, Johnson & Johnson Innovation

11:10 – 11:30 | FIRESIDE CHAT
Mathai Mammen, Global Head, R&D, Janssen; George Yancopoulos, President & CSO, Regeneron
Moderator: Christoph Westphal, General Partner, Longwood Fund

11:30 – 12:00 | THE EVOLVING NEEDS OF R&D
Hal Barron, Head, R&D, GlaxoSmithKline; Jay Bradner, President, Novartis Institutes for BioMedical Research; Tom Hudson, SVP, R&D, CSO, AbbVie; Aakanksha Khandelwal, Head, Global Portfolio Strategy & Innovation, EMD Serono; Frank Nestle, Global Head, Research, CSO, Sanofi
Moderator: Ray Deshaies, Head, Global Research, Amgen

12:00 – 12:20 | FIRESIDE CHAT
John Maraganore, CEO, Alnylam; Janet Woodcock, Commissioner, FDA
Moderator: Christoph Westphal, General Partner, Longwood Fund

12:20 – 12:50 | ALTERNATIVE SOURCES OF FUNDING
Mike Boyle, CEO, CF Foundation; Sophie Kornowski, Senior Partner, Gurnet Point Capital; Paul Lammers, CEO, Triumvira; Stephen Lesser, Vice President, NovaQuest
Moderator: Bill Hicks, Co-Chair, Securities & Capital Markets Practice, Mintz

12:50 – 1:20 | GOING GLOBAL: WORKING ACROSS INTERNATIONAL MARKETS
Thierry Bernard, CEO, Qiagen; Aoife Brennan, CEO, Synlogic; Ivan Cheung, Chair & CEO, Eisai US; Björn Frendéus, CSO, BioInvent; Trish Hurter, CEO, Lyndra
Moderator: Stephen Uden, Co-Founder, RallyBio

1:20 – 1:50 | TAPPING INTO INNOVATION: BIOPHARMA HUBS
John Flavin, Chair, Pyxis Oncology; Joel Marcus, Chair, Alexandria Real Estate; Lloyd Minor, Dean, Stanford School of Medicine; Iskra Reic, EVP, Europe & Canada at AstraZeneca
Moderator: Chandra Ramanathan, Global Head, Pharma R&D, Open Innovation, Bayer

1:50 – 2:20 | DIVERSITY, INCLUSION, AND EQUITY IN BIOPHARMA
Alisha Alaimo, President, US, Biogen; Julie Kampf, CEO, JBK Associates; Rob Perez, Founder & Chair, Life Science Cares; Ramona Sequeira, President, Takeda Pharmaceuticals USA
Moderator: Ron Cooper, CEO, Albireo Pharma

2:20 – 2:50 | DESIGNING THE DEAL
Mary Lynne Hedley, Senior Fellow, Broad Institute; Lucy Liu, Senior Associate, Longwood Fund; Phil McGurk, Head, East Coast BD & Acquisitions, AbbVie; Patrick Verheyen, Global Head, Business Development, Janssen; Jonathan York, VP, Global BD, Daiichi Sankyo
Moderator: Chad Shear, Principal, Fish & Richardson

2:50 – 3:10 | FIRESIDE CHAT
Andy Plump, President, R&D, Takeda; John Reed, EVP, Global Head, RD, Sanofi
Moderator: Christoph Westphal, General Partner, Longwood Fund

3:10 – 3:40 | NAVIGATING REGULATORY CHALLENGES
Dietmar Berger, CMO, Global Head, Development, Sanofi; PJ Brooks, Program Director, NIH; Priti Hegde, CSO, Foundation Medicine; Lynn Kramer, Chief Clinical Officer, Eisai; John Orloff, EVP, Head, R&D, Alexion
Moderator: Art Krieg, CSO, Checkmate Pharmaceuticals

3:40 – 4:10 | THE UPS, DOWNS, AND UPS OF DRUG APPROVAL
JJ Bienaime, CEO, BioMarin; Barry Greene, CEO, Sage Therapeutics; Ted Love, CEO, Global Blood Therapeutics; Bill Mezzanotte, EVP, Head, R&D, CSL Behring; Raquel Mura, Head of R&D North America, Sanofi
Moderator: Gaurav Shah, CEO, Rocket Pharmaceuticals

4:10 – 4:30 | FIRESIDE CHAT
Ruxandra Draghia-Akli, Global Head, Global Public Health R&D, Johnson & Johnson; Rehan Verjee, President, Global Head, Innovative Medicines, EMD Serono
Moderator: David Steinberg, General Partner, Longwood Fund

4:30 – 5:00 | AFTER IPO: MAINTAINING MOMENTUM
Al Beardsley, COO, Galera Therapeutics; Sarah Boyce, CEO, Avidity Biosciences; Aaron Schwimmer, Managing Director, Barclays Bank; Dan Omstead, CEO, Tekla Capital Management
Moderator: Dan Paterson, COO & President, Verastem

5:00 – 5:10 LONGWOOD FUND SUMMARY

Christoph Westphal, General Partner, Longwood Fund

 

 

TUESDAY, APRIL 6, 2021

7:00 – 7:30 | LONGWOOD FUND INTRODUCTION
Rich Aldrich, General Partner, Longwood Fund; John Lawrence, CFO, Longwood Fund; David Steinberg, General Partner, Longwood Fund; Christoph Westphal, General Partner, Longwood Fund

7:30 – 8:00 | PROGRESS TOWARDS SUSTAINABLE TREATMENTS AND VACCINES FOR COVID-19
Michael Mina, Asst Professor, Epidemiology, Harvard School of Public Health; Melissa Moore, CSO, Moderna; Ryan Richardson, Chief Strategy Officer, BioNTech; Stan Erck, President & CEO, Novavax

8:00 – 8:30 | NOVEL THERAPEUTIC MODALITIES
Bill Hinshaw, CEO, Axcella Health; Laura Sepp-Lorenzino, CSO, Intellia; Angela Shen, CMO, Arcellx
Moderator: Roger Tung, CEO, Concert Pharmaceuticals

8:30 – 8:50 | FIRESIDE CHAT
Tyler Jacks, Director, MIT Koch Institute for Integrative Cancer Research; Bob Langer, Co-Founder, Moderna/Momenta, Nobelist, NAS; Phil Sharp, Co-Founder, Biogen/Alnylam, Nobelist, NAS
Moderator: Christoph Westphal, General Partner, Longwood Fund

8:50 – 9:20 | BIG BIOPHARMA R&D
José Baselga, EVP, R&D, Oncology, AstraZeneca; Teri Foy, SVP, IO & Cellular Therapy, Bristol Myers Squibb; Steve Hitchcock, Head, Research, Takeda; Philip Larsen, Global Head, Research, Bayer Pharmaceuticals; Richard Staub, President, R&D Solutions, IQVIA

9:20 – 9:50 | ENSURING DIAGNOSTIC ACCURACY AND EFFICIENCY
Mark Stevenson, COO, Thermo Fisher Scientific; Alan Wright, CMO, Roche Diagnostics; David R. Walt, Co-Director, MGB Center for COVID Innovation, Harvard Medical School; Joshua Ofman, CMO and External Affairs, Grail Bio
Moderator: Lea Hachigian, founding CEO, ImmuneID and Principal, Longwood Fund

9:50 – 10:20 | DRIVING INNOVATION IN CELL THERAPY
Richard James, Associate Professor, University of Washington; David Rawlings, Director, Center for Immunity and Immunotherapies, Seattle Children's Research Institute; Lea Hachigian, Principal, Longwood Fund; Frances Eun-Hyung Lee, Associate Professor, Emory; Jason Rhodes, Partner, Atlas Ventures
Moderator: Aleks Radovic-Moreno, Venture Partner, Longwood Fund

10:20 – 10:40 | FIRESIDE CHAT
Betsy Nabel, President, Brigham Health; Laurie Glimcher, CEO, Dana-Farber Cancer Institute

Moderator: David Steinberg, General Partner, Longwood Fund

10:40 – 11:10 | EXPEDITING THE PATH TO PATIENT CARE
Fiona Elwood, Head, Neuroscience, Novartis; Cedric Francois, CEO, Apellis; Eileen Maus, CEO, Renovia Inc; Maria Rivas, CMO, Merck KGaA; Clay Siegall, CEO, Seattle Genetics
Moderator: Jeremy Levin, CEO, Ovid Therapeutics

11:10 – 11:40 | LEVERAGING AI TO TRANSFORM DRUG DISCOVERY AND DEVELOPMENT
Milind Kamkolkar, CDO, Cellarity; Brian Martin, Head, AI, AbbVie; Venky Soundararajan, CSO, nference
Moderator: Robert Gentleman, Founding Executive Director, Center for Computational Biomedicine, Harvard Medical School

11:40 – 12:00 | FIRESIDE CHAT
David Reese, EVP, R&D, Amgen; Rupert Vessey, President, Research & Early Development, Bristol Myers Squibb
Moderator: Christoph Westphal, General Partner, Longwood Fund

12:00 – 12:30 | EXTERNAL INNOVATION
Roger Palframan, Head, External Innovation, UCB; Diana Gallagher, Head, External Innovation & New Indications, Biogen; Bob Silverman, CBO, Alloy Therapeutics; Priyanka Rohatgi, Managing Director, Ventures, Ipsen
Moderator: Uwe Schoenbeck, CSO, External R&D, Pfizer

12:30 – 1:00 | MAKING A BIG IMPACT WITH LIMITED RESOURCES
Chris Garabedian, CEO, Xontogeny; Jeb Keiper, CEO, Nimbus Therapeutics; Martin Mackay, Co-Founder, RallyBio; Adelene Perkins, CEO, Infinity Pharmaceuticals; Neil Weir, CEO, Sitryx
Moderator: David Meek, CEO, FerGene

1:00 – 1:30 | SCIENTIFIC INNOVATION: LAUNCHING COMPANIES FROM ACADEMIA
Omar Abudayyeh, Fellow, McGovern Institute; Bill Hait, Global Head, External Innovation, Johnson & Johnson; Rachel Haurwitz, CEO, Caribou Biosciences; Lizzie Ngo, Senior Associate, Longwood Fund; Kai Wucherpfennig, Chair, Cancer Immunology and Virology, Dana-Farber Cancer institute
Moderator: Paul Schimmel, Professor, Cell & Molecular Biology, Scripps

1:30 – 1:50 | MEDIA PERSPECTIVES ON BIOPHARMA
Matthew Herper, Senior Writer, Medicine, Stat News; Karen Weintraub, Journalist, USA Today
Moderator: Christoph Westphal, General Partner, Longwood Fund

2:00 – 2:30 | ALIGNING PRIORITIES WITH THE BOARD
Anirvan Ghosh, CEO, Unity Biotechnology; Henry Gosebruch, Chief Strategy Officer, AbbVie; Myrtle Potter, CEO, Sumitovant
Moderator: Ramani Varanasi, CEO, X-Biotix

2:30 – 3:00 | DIFFERENTIATION IN ONCOLOGY
Philip Astley-Sparke, CEO, Replimune; Axel Hoos, SVP, R&D Governance Chair & Head, Oncology, GlaxoSmithKline; Pearl Huang, CEO, Cygnal Therapeutics; Armon Sharei, CEO, SQZ Biotech; Zhen Su, SVP, Head, Global Oncology, Merck KGaA

Moderator: Teresa Bitteti, President, Oncology, Takeda

3:00 – 3:30 | INNOVATIVE PARTNERSHIPS
Jennifer Cayer, CBO, Pulmocide; Alban de La Sabliere, Head, M&A, Sanofi; Doug Giordano, SVP, WWBD, Pfizer; Ioannis Sapountzis, Global Head, BD&L, Boehringer Ingelheim; Kimberly Smith, SVP, Head of R&D, ViiV Healthcare
 

3:30 – 3:50 | FIRESIDE CHAT

Francis deSouza, CEO, Illumina; Skip Virgin, CSO, VIR

Moderator: Christoph Westphal, General Partner, Longwood Fund

3:50 – 4:20 | PERSPECTIVES ON HEALTHCARE REFORM AND PRICING
Peter Kolchinsky, Managing Director, RA Capital; Peter Rubin, Executive Director, No Patient Left Behind

4:20 – 4:50 | DEALS WITHIN THE VENTURE NETWORK
Ansbert Gadicke, Managing Director, MPM Capital; Bob Nelsen, Managing Director, ARCH Venture Partners; Aleks Radovic-Moreno, Venture Partner, Longwood Fund; Jeff Stevens, Principal, Alexandria Venture Investments
Moderator: Dustin Tyner, Managing Director, Jefferies Investment Banking

4:50 – 5:00 | LONGWOOD FUND SUMMARY

Lea Hachigian, Principal, Longwood Fund; Aleks Radovic-Moreno, Venture Partner, Longwood Fund
Moderator: David Steinberg, General Partner, Longwood Fund

Supporters

We are grateful to the following organizations for their support of this meeting. To learn more about getting involved contact susan@longwoodfund.com

Cytiva

Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. Formerly part of GE Healthcare Life Sciences, we have a rich heritage tracing back hundreds of years, and a fresh beginning since 2020. Our customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Our job is to supply the tools and services they need to work better, faster and safer, leading to better patient outcomes.

JBK

JBK Associates International is a woman-owned, global executive search firm that is a leader in the recruitment and retention of diverse talent across a wide spectrum of industries with exceptional depth in the Life Sciences.  Our D&I expertise spans 19 years and supports our client's strategy for creating the most inclusive organizations with the greatest ROI.  We bring great leaders to great companies.  jbkassociates.net

Mintz

Mintz is a versatile Am Law 100 law firm with 500 attorneys serving clients worldwide. We collaborate across disciplines to deliver exceptional legal strategies that help clients navigate shifting industry challenges. Our attorneys advise business leaders, entrepreneurs, and investors on pivotal deals, disputes, and regulatory matters. We work within four core practice areas—Transactional, Intellectual Property, Litigation & Investigations, and Regulatory & Advisory—and serve industries including the life sciences; health care; technology; insurance & financial services; energy & sustainability; sports & entertainment; real estate, construction & infrastructure; retail & consumer products; and education & nonprofit sectors.  Visit us at www.mintz.com

Replimmune

Replimune is pioneering a new class of oncolytic immunotherapies (OI) designed to ignite a powerful patient-specific immune response to treat cancer and vaccinate against future relapse. The company’s Immulytic™ platform is intended to achieve the holy grail of personalized anti-cancer treatments — combining multiple mechanisms of action to deliver therapies with the ability to directly kill tumors and generate systemic anti-cancer immune responses. Since September 2015, Replimune has built a portfolio of product candidates with three programs currently in the clinic. Its lead program, RP1, is in two registration directed clinical trials – in cutaneous squamous cell carcinoma and anti-PD1 failed melanoma-– and is also being tested in other tumor types, including anti-PD1 failed non-small cell lung cancer. Two further product candidates, RP2 and RP3, are currently in Phase 1 clinical development. Replimune has completed buildout of its 63,000-square-foot state-of-the-art GMP manufacturing facility which will support later-stage development and full commercialization of all of its products. 

Fish & Richardson

Fish & Richardson, a premier global intellectual property (IP) law firm, works with pioneering life sciences companies to help them achieve their strategic IP goals through partnering, licensing, financing, acquisition, and enforcement. We do this by bringing a unique, holistic approach to our clients’ IP matters, fostered by the collaboration between our patent prosecution, litigation, and regulatory practices. We have helped our clients build valuable patent portfolios worth billions of dollars, score big victories at the Patent Trial and Appeal Board (PTAB), and win bet-the-company cases in court. When life sciences clients come to Fish to build an IP strategy, they know that we will leave no stone unturned when crafting creative and comprehensive solutions to maximize the value of their IP.

IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry dedicated to delivering actionable insights. Learn more at www.iqvia.com.

Huron

Biopharmaceutical and medical device companies remain under pressure to navigate ever-changing environments. We work with our clients to innovate and improve health outcomes while justifying product value. Huron’s life sciences business is part of Huron’s continuum of healthcare offerings supporting the development and commercialization of technologies in these companies.

Discover how Huron can help you to harness new developments and stay ahead of the curve.

•             Corporate and Franchise Strategy

•             Commercial Strategy

•             R&D Strategy

•             Business Development Strategy

•             Market Access and Pricing

Longwood Healthcare Leaders meetings are off-the-record without the presence of media. All participants are asked not to post anything shared in discussion to social media. Meetings are currently planned either solely via webconference or predominantly via webconference.

Cancellation policy:  If a participant needs to cancel attendance, we are pleased to allow transfer of registration to a colleague or to the next meeting.  In the case of postponement of an event, all registrations will be accepted for a rescheduled or subsequent meeting.

© 2020 Longwood Healthcare Leaders